Fortress Biotech, Inc. - 16 Apr 2024 Form 4 Insider Report for AVENUE THERAPEUTICS, INC. (ATXI)

Role
10%+ Owner
Signature
/s/ Samuel Berry, General Counsel and Authorized Agent
Issuer symbol
ATXI
Transactions as of
16 Apr 2024
Net transactions value
$0
Form type
4
Filing time
17 Apr 2024, 16:05:19 UTC
Previous filing
22 Mar 2024
Next filing
24 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATXI COMMON STOCK, PAR VALUE $0.0001 Award $0 +413,507 +13% $0.000000 3,547,393 16 Apr 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Fortress Biotech, Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. 413,507 shares were granted by the Issuer to the Reporting Person following the closing of an equity financing.